28 June 2020: Articles
Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Ali Elbeddini A* , Naushin Hooda A , Mohamed Gazarin B , Penny Webster B , Jackie McMillan BDOI: 10.12659/AJCR.924058
Am J Case Rep 2020; 21:e924058
Table 1. Summary of patient cases.
| Patient (A) | Patient (B) | Patient (C) | |
|---|---|---|---|
| 56/F | 72/F | 68/F | |
| Pancreatic cancer, metastatic | Pancreatic cancer, adjuvant | Pancreatic cancer, resected | |
| FOLFIRINOX | FOLFIRINOX | FOLFIRINOX | |
| Slurred speech, “funny tongue feeling”, mild chest tightness, mild light-headedness | “Mouth is paralyzed”, slight slurred speech, “hot flash” | “Thick tongue”, vision changes, difficult with speech | |
| Neuropathy | None | None | |
| 10 | Immediately | 10 | |
| 180 | 180 | 180 | |
| 6 | 3 | 8 |